What changed for Myeloma
A plain English summary of what recently moved in the public data Voxsanity tracks for Myeloma. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 499 to 493 (-6)
- Trials on record 2,670 to 2,686 (+16)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Myeloma in July 2026. Voxsanity tracks 11 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 186 trials tracked for Myeloma that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT04504825 · results posted 2 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04504825) enrolled 125 participants in total — 84 received CAEL-101 (an investigational drug) alongside standard treatment for their underlying blood disorder, while 41 received a placebo alongside the same standard treatment. The trial was primarily measuring two things: how long participants survived overall, and how often they were hospitalised for heart-related reasons. These two outcomes were combined into a single scoring method (called a "win ratio") that compares pairs of participants to see whose outcome was relat...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT07150104 · results posted 25 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 14 participants, all of whom received a combination of four medicines: belantamab mafodotin (at a dose of 0.5 mg/kg), nirogacestat, pomalidomide, and dexamethasone. The trial was studying this combination in a dose-exploration phase (to assess tolerability of the dose) and was measuring things like unwanted medical events experienced by participants, changes in blood test results, and how many participants' disease responded to the treatment combination. The reported data shows that all 14 participants experienced at...
-
NCT07217119 · results posted 25 June 2026
According to the results reported on ClinicalTrials.gov, this trial looked at two investigational medicines — belantamab mafodotin and feladilimab — given together in different dose combinations to people with a type of blood cancer called multiple myeloma. A total of 25 people took part across three groups: 9 people received the lower dose of belantamab mafodotin (1.9 mg/kg) combined with the lower dose of feladilimab (8 mg); 10 people received the higher dose of belantamab mafodotin (2.5 mg/kg) with the lower feladilimab dose (8 mg); and 6 people received the higher dose of belantamab mafodo...
-
NCT07217184 · results posted 25 June 2026
According to the results reported on ClinicalTrials.gov, this trial tested two different medicines given together — belantamab mafodotin and isatuximab — in people with a blood cancer called multiple myeloma. Thirty participants in total were enrolled, split evenly across three groups of 10, each receiving a different dose or dosing schedule of belantamab mafodotin alongside isatuximab. The trial was primarily measuring safety-related events, including whether serious dose-related reactions (called "dose-limiting toxicities") occurred, as well as tracking any unwanted medical events (called "a...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04512235 · results posted 17 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 281 people in total — 187 received the study drug CAEL-101 alongside standard treatment for their underlying blood disorder, and 94 received a placebo (an inactive dummy treatment) alongside the same standard treatment. The trial was primarily looking at two things: how long participants survived, and how often they needed to be admitted to hospital for heart-related reasons. It also looked at participants' quality of life, how far they could walk in six minutes, and overall death rates. The reported data shows that...
-
NCT07150091 · results posted 16 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 20 people in total — 10 in a lower-dose group receiving 0.5 mg/kg of belantamab mafodotin combined with nirogacestat, lenalidomide, and dexamethasone, and 10 in a higher-dose group receiving 1.0 mg/kg of the same combination. The trial was studying a four-drug combination for what appears to be a blood cancer (based on the response criteria used), and was looking at two things: first, a "dose exploration" phase to understand safety signals and side effects at each dose level, and second, a "confirmatory expansion" pha...
-
NCT04824794 · results posted 19 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04824794) tested an investigational treatment called GEN3014 across several groups of people with different blood cancers — including relapsed or refractory multiple myeloma (a blood cancer affecting plasma cells), relapsed or refractory acute myeloid leukaemia (a type of blood cancer), and relapsed or refractory diffuse large B-cell lymphoma (an aggressive form of lymphoma). In total, 131 people took part across all groups. The trial had two main phases: a dose-escalation phase (where researchers gradually increased the d...
-
NCT07084896 · results posted 6 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled a total of 106 participants across seven different treatment groups. The trial was studying two drugs — belantamab mafodotin and nirogacestat — used together or separately in people with a blood cancer called multiple myeloma. The trial had two phases: a dose-exploration (DE) phase, where researchers tested different dose combinations across five groups (35 participants in total), and a cohort-expansion (CE) phase, where two larger groups (34 and 37 participants respectively) received doses selected from the earlier p...
-
NCT02316106 · results posted 23 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT02316106) involved 123 people with a condition called smouldering multiple myeloma — a form of the disease that has not yet caused symptoms. Participants were divided equally into three groups of 41, each receiving a different treatment schedule using the drug daratumumab: a long intensive schedule (Arm A), an intermediate schedule (Arm B), and a short intensive schedule (Arm C). The trial was measuring things like how many people achieved a complete response (meaning no detectable signs of the disease in blood, urine, or...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02773030 · results posted 20 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT02773030) enrolled a total of around 500 participants across a large number of different treatment groups, organised into several "cohorts" (labelled A through K). Each cohort tested a different drug combination or dose level. The trial was primarily measuring two things: first, how many participants in the early dose-finding phase experienced what researchers call a "dose-limiting toxicity" — meaning a side effect serious enough to cap or stop increasing the dose; and second, the "overall response rate" in two specific co...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04850846 · results posted 9 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04850846) enrolled 60 people in total — 30 in a group receiving metformin (a medication commonly used for diabetes) and 30 in a group receiving a placebo (a dummy treatment with no active ingredient). The trial was measuring changes in a protein in the blood called M-protein, which is associated with a type of blood condition. By the end of the study, 22 people in the metformin group and 23 in the placebo group had completed the trial, meaning 8 and 7 people respectively did not finish. The reported data shows that, for t...
-
NCT03301220 · results posted 23 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03301220) enrolled 390 people in total — 196 in a group receiving active monitoring only (meaning they were closely watched but not given the study drug), and 194 in a group receiving a medicine called daratumumab SC (given by injection under the skin). The trial was studying people with a condition that can be a forerunner to multiple myeloma (a type of blood cancer), and the main thing being measured was "progression-free survival" — that is, how long participants went without their condition worsening into active multip...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03317899 · results posted 17 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 77 people in total — 38 in one group who received a stem cell transplant along with a drug called tbo-filgrastim (a medicine given after transplant to encourage the body to make new blood cells), and 39 in a second group who received the stem cell transplant without that drug. The trial was mainly looking at how many days it took before each person was considered ready to leave hospital after their transplant. It also tracked several other measurements, including how long it took for two types of blood cells — white c...
-
NCT05405166 · results posted 14 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05405166) enrolled 531 adults with a blood cancer called multiple myeloma. Participants were randomly assigned to one of two groups: 268 people received isatuximab given through a drip into a vein (intravenous, or "IV"), combined with two other medicines (pomalidomide and dexamethasone); and 263 people received the same isatuximab combination but delivered as an injection under the skin (subcutaneous, or "SC"). The trial was measuring how often patients responded to treatment, how much of the drug was present in the blood...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04439149 · results posted 31 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04439149) enrolled 24 participants who received the study treatment, a drug called GSK2636771. Of those, 23 began the treatment as planned, and 22 were considered eligible and treated for the purposes of analysis. No participants were recorded as having formally completed the study. The trial was measuring how cancer tumours responded to the treatment, and how long participants went without their disease getting worse. The reported data shows that for the primary goal — the rate at which tumours showed a measurable shrink...
-
NCT05961215 · results posted 27 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 31 participants, all of whom used the Penguin Cold Cap — a device worn during chemotherapy that cools the scalp with the aim of reducing hair loss. Thirty participants completed the trial and one did not. The trial was measuring how much hair loss participants experienced while using the cap, and also asked participants to rate how beneficial they felt the scalp cooling was for them. The reported data shows that of the 30 participants counted in the primary outcome, 26 were recorded as having less than 50% hair loss...
-
NCT05064358 · results posted 7 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05064358) enrolled 177 participants across five groups, all receiving different doses and schedules of a medicine called belantamab mafodotin. The groups varied by dose (either 2.5 mg per kilogram of body weight, or 1.9 mg/kg) and how often the dose was given (every 3 weeks or every 6 weeks). The trial was primarily measuring how often participants developed moderate-to-severe eye changes — specifically changes to the cornea (the clear front surface of the eye) that also affected their vision — as graded on a standardised...
-
NCT06063603 · results posted 18 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06063603) enrolled 59 people across three groups: 51 patients receiving pain management (Group 1), 5 healthcare providers who delivered the intervention (Group 2), and 3 medical oncology providers (Group 3). The trial was designed to test whether a pain management intervention was *feasible* (could it be delivered as intended?), *acceptable* (were participants satisfied with it and did they engage with their care team?), and *useful* (did participants find it helpful, feel confident, and find it easy to use?). Of the 51 pa...
-
NCT03078452 · results posted 8 September 2025
According to the results reported on ClinicalTrials.gov, this trial involved 100 people in total — 50 in each group. All 100 participants completed the study. The trial was comparing two different tools used to take a bone marrow biopsy (a procedure where a small sample of bone marrow is removed for testing): one group had their biopsy taken using a power drill device, and the other group had theirs taken using a traditional hand-held needle called a Jamshidi needle. The trial measured the size of the tissue sample collected, how long the procedure took, and how much pain participants reported...
-
NCT06400251 · results posted 26 August 2025
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called ipatasertib in people with certain cancers. A total of 35 people enrolled in the study, 34 began taking the treatment, and 32 were considered eligible and treated. Of those, 29 had their mutation status confirmed, and this smaller group of 29 people formed the main group used to assess the primary result. The trial was measuring how often tumours shrank or disappeared (called "objective response rate"), as well as how long people went without their disease getting worse (called "progression-free surviva...
-
NCT05655546 · results posted 8 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05655546) involved 1,016 people in total — 495 in the intervention arm and 521 in the control arm. Nearly all participants finished the study (493 and 517 respectively). The trial was measuring two main things: how many participants ended up in hospital related to COVID-19 (tracked through insurance claims and self-reported surveys), and what the total cost of care for COVID-19 was in each group. The reported data shows that when it came to hospitalisations, the numbers recorded across different data sources varied betwee...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05590377 · results posted 6 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05590377) looked at a combination of two medicines — modakafusp alfa and daratumumab — in people with a blood cancer called multiple myeloma. The trial had two stages: a Phase 1 dose-escalation stage, where researchers tested three different doses of modakafusp alfa (80 mg, 120 mg, and 240 mg) to understand how the body responded; and a planned Phase 2a stage, which aimed to narrow down the best dose. A total of 15 participants started the trial across the Phase 1 dose groups (3 at 80 mg, 6 at 120 mg, and 6 at 240 mg), and...
-
NCT02675452 · results posted 9 July 2025
According to the results reported on ClinicalTrials.gov, this trial tested an experimental drug called AMG 176 in people with either multiple myeloma (a type of blood cancer affecting plasma cells) or acute myeloid leukaemia (AML, a cancer of the blood and bone marrow). A total of 168 participants took part, spread across 29 different groups that each received different doses or dosing schedules of AMG 176 — some alone and some combined with other medicines such as azacitidine or itraconazole. The trial was a dose-finding study, meaning its main goal was to test different dose levels rather th...
-
NCT04181827 · results posted 20 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04181827) enrolled 419 people with multiple myeloma — 211 in the standard therapy group (receiving a drug combination called PVd or DPd) and 208 in the group receiving an experimental cell-based treatment called ciltacabtagene autoleucel (cilta-cel). The trial's main goal was to measure how long participants went without their disease getting worse or dying — a period known as "progression-free survival." The reported data shows that in the standard therapy group, the median progression-free survival — meaning the point a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01054196 · results posted 13 May 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 52 people in total across two stages. The first stage (Phase 1) involved 22 participants split into six smaller groups, each receiving a different dose level of a drug called lenalidomide combined with another drug called melphalan. The aim was to find the highest dose of lenalidomide that could be added without causing unacceptable side effects — this is called the "maximum tolerated dose." The second stage (Phase 2) enrolled 30 participants and focused on measuring how long any positive response to the treatment las...
-
NCT06868667 · results posted 9 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06868667) enrolled 24 people with a form of blood cancer called multiple myeloma. Ten participants received a combination of three medicines — belantamab mafodotin, bortezomib, and dexamethasone — while 14 received a different three-medicine combination of daratumumab, bortezomib, and dexamethasone. The main thing the trial was measuring was "progression-free survival" — that is, how long participants went without their disease getting worse or dying. None of the 24 participants had completed the study at the time the resu...
-
NCT04892446 · results posted 2 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04892446) enrolled 36 people with multiple myeloma across three treatment groups: 15 people received magrolimab combined with daratumumab, 10 received magrolimab combined with pomalidomide and dexamethasone, and 11 received magrolimab combined with carfilzomib and dexamethasone. The trial was primarily measuring how often participants experienced certain serious side effects (called dose-limiting toxicities) and other unwanted medical events that occurred during treatment, as well as how many participants showed a measurab...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04439331 · results posted 8 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04439331) tested a drug called defactinib in people with certain cancers. A total of 35 people enrolled in the study, 33 of them began the treatment, and 30 had their eligibility and tumour mutation status fully confirmed. No participants were recorded as having "completed" the study in the conventional sense — this is common in cancer trials where participants leave the study early due to disease progression or other reasons. The reported data shows that the main thing researchers were measuring was the "objective respon...
-
NCT03748953 · results posted 21 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03748953) looked at a medicine called ixazomib in people with a blood cancer called multiple myeloma. The trial originally had two groups — one receiving ixazomib and one receiving a placebo (a dummy treatment) — but the design changed partway through. In total, 41 people started the ixazomib group across both phases of the trial, while 4 people were in the placebo group before that arm was removed. The trial was primarily measuring participants' physical health status, as well as tracking unwanted medical events (called a...
-
NCT04484623 · results posted 18 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04484623) enrolled 302 people with multiple myeloma — 155 in one group and 147 in another. Participants were randomly assigned to receive either a combination of three medicines called belantamab mafodotin, pomalidomide, and dexamethasone, or a different three-medicine combination of pomalidomide, bortezomib, and dexamethasone. The trial's main goal was to measure "progression-free survival" — that is, how long participants went without their disease getting worse or without dying. The reported data shows that for the mai...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 186 reported results for Myeloma
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, myeloma currently attracts a very large amount of public research investment from the United States, and that level of funding has remained broadly steady over recent years. For patients, this signals that myeloma is an established research priority with a sustained scientific community working on it. Consistent funding at this level generally supports a wide range o...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.